Influence of Naive Lymphocyte Repertoire Size on Vaccination Efficancy
Influence of Naive Lymphocyte Repertoire Size on Vaccination Efficancy
批准号:
7808944
负责人:
Marc Kevin Jenkins
金额:
$45.88万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-09-27 至 2012-08-31
关键词:
AccountingAdultAnimalsAntibodiesAntibody FormationAntigensB-LymphocytesBindingBiological MarkersCD4 Positive T LymphocytesCellsComplexDetectionFluorochromeGoalsHLA-DR AntigensHealthHelper-Inducer T-LymphocyteHepatitis BHepatitis B Surface AntigensHepatitis B VirusHumanImmuneImmune responseImmunityImmunizationIndividualInfectionLabelLeadLymphocyteMajor Histocompatibility ComplexMeasuresMemoryMethodsPeptidesPopulationReagentSolutionsSubunit VaccinesSystems BiologyTestingVaccinatedVaccinationVaccinesVariantVirus Diseasesbaseimprovedinnovationmagnetic beadsnovelperipheral bloodpreventpublic health relevanceresponsetheoriestoolvaccine-induced immunity
中文摘要
描述(由申请人提供):人类对感染和免疫的免疫反应-通过现代免疫学方法和系统生物学进行分析。B型肝炎亚单位疫苗通过诱导预防病毒感染的抗体而在数百万人中诱导免疫力。然而,不同个体中对疫苗的B型肝炎表面抗原(HBS)组分的抗体应答的变异性非常大,并且一些个体不能完全应答。我们认为,这种变异性提供了一个黄金机会,了解人类免疫反应的多样性接种疫苗,并确定免疫反应的相关性。本申请的中心假设是免疫前库中幼稚抗原特异性B细胞和/或CD 4+辅助T细胞的数量决定了抗体应答的大小。我们将使用我们开发的超灵敏方法来检测接种疫苗前后人体中的HBS特异性B细胞和HBS肽-主要组织相容性复合物II特异性CD 4+辅助T细胞,以检验这一假设。本提案的目标是开发用于全面分析人类HBs特异性幼稚T和B细胞所需的试剂,然后使用这些工具来确定接种后抗体滴度的大范围是否由免疫前库的变化来解释。这种创新的方法可以提供疫苗反应的最终生物标志物-疫苗特异性淋巴细胞本身-并为如何改进疫苗以保护所有个体提供指导。
公共卫生相关性:这些研究是相关的,因为它们有可能解释为什么某些人在接受B型肝炎亚单位疫苗后没有产生特异性抗体。我们的理论是,这些人在接种疫苗前缺乏相关的淋巴细胞。如果这一理论是正确的,那么这些人如果接种了不同的B型肝炎亚单位,应该会产生抗体。因此,这些研究有可能预测哪些人对这种重要的疫苗没有反应,并提出解决这一问题的方法。
英文摘要
DESCRIPTION (provided by applicant): The human immune response to infection and immunization - Profiling via modern immunological methods and systems biology. The Hepatitis B subunit vaccine induces immunity in millions of people by inducing antibodies that prevent viral infection. However, the variability in the antibody response to the Hepatitis B surface antigen (HBS) component of the vaccine in different individuals is remarkably large and some individuals fail to respond altogether. We propose that this variability provides a golden opportunity to understand the diversity of human immune responses to vaccination and identify immune response correlates. The central hypothesis of this application is that the number of naive antigen-specific B cells and/or CD4+ helper T cells in the pre-immune repertoire dictates the magnitude of the antibody response. We will test this hypothesis using an ultra sensitive method that we developed to detect HBS-specific B cells and HBS peptide-Major Histocompatibilty Complex II-specific CD4+ helper T cells in humans before and after vaccination. The goals of this proposal are to develop the reagents needed for comprehensive analysis of the HBS-specific naive T and B cells in humans and then use these tools to determine whether or not the great range in postvaccination antibody titer is explained by variations in the pre-immune repertoire. This innovative approach could provide the ultimate biomarker of vaccine response - the vaccine-specific lymphocytes themselves - and provide direction as to how the vaccine could be improved to protect all individuals.
PUBLIC HEALTH RELEVANCE: These studies are relevant because they have the potential to explain why certain people do not develop specific antibodies after receiving the Hepatitis B subunit vaccine. Our theory is that these individuals lack the relevant lymphocytes before vaccination. If this theory is correct, then these individuals should develop antibodies if vaccinated with a different Hepatitis B subunit. Therefore, these studies have the potential to predict who will not respond to this important vaccine and suggest a solution to this problem.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Detection and Activation of CD4+ T cells with Low Affinity TCRs
-
批准号:10348758
-
项目类别:
-
资助金额:$38.32万
-
财政年份:2019
-
负责人:Marc Kevin Jenkins
-
依托单位:
Detection and Activation of CD4+ T cells with Low Affinity TCRs
-
批准号:10570243
-
项目类别:
-
资助金额:$38.32万
-
财政年份:2019
-
负责人:Marc Kevin Jenkins
-
依托单位:
Protective CD4+ T Cells
-
批准号:10349513
-
项目类别:
-
资助金额:$46.74万
-
财政年份:2013
-
负责人:Marc Kevin Jenkins
-
依托单位:
Protective CD4+ T cells
-
批准号:8430702
-
项目类别:
-
资助金额:$35.72万
-
财政年份:2013
-
负责人:Marc Kevin Jenkins
-
依托单位:
Protective CD4+ T cells
-
批准号:8810212
-
项目类别:
-
资助金额:$38.0万
-
财政年份:2013
-
负责人:Marc Kevin Jenkins
-
依托单位:
Protective CD4+ T cells
-
批准号:9022392
-
项目类别:
-
资助金额:$38.0万
-
财政年份:2013
-
负责人:Marc Kevin Jenkins
-
依托单位:
Analysis of peripheral tolerance in vivo
-
批准号:8500973
-
项目类别:
-
资助金额:$14.88万
-
财政年份:2013
-
负责人:Marc Kevin Jenkins
-
依托单位:
Protective CD4+ T cells
-
批准号:8634713
-
项目类别:
-
资助金额:$38.0万
-
财政年份:2013
-
负责人:Marc Kevin Jenkins
-
依托单位:
Protective CD4+ T cells
-
批准号:9228319
-
项目类别:
-
资助金额:$38.0万
-
财政年份:2013
-
负责人:Marc Kevin Jenkins
-
依托单位:
Analysis of peripheral tolerance in vivo
-
批准号:8308579
-
项目类别:
-
资助金额:$33.06万
-
财政年份:2011
-
负责人:Marc Kevin Jenkins
-
依托单位:
Flow Cytometry Core
-
批准号:8308583
-
项目类别:
-
资助金额:$10.78万
-
财政年份:2011
-
负责人:Marc Kevin Jenkins
-
依托单位:
Modular Subunit Vaccine for Salmonella
-
批准号:8298298
-
项目类别:
-
资助金额:$37.19万
-
财政年份:2011
-
负责人:Marc Kevin Jenkins
-
依托单位:
Flow Cytometry Core
-
批准号:7166127
-
项目类别:
-
资助金额:$8.82万
-
财政年份:2006
-
负责人:Marc Kevin Jenkins
-
依托单位:
Analysis of peripheral tolerance in vivo
-
批准号:7166122
-
项目类别:
-
资助金额:$27.82万
-
财政年份:2006
-
负责人:Marc Kevin Jenkins
-
依托单位:
2006 FASEB SRC on Lymphocytes and Antibodies
-
批准号:7161177
-
项目类别:
-
资助金额:$1.1万
-
财政年份:2006
-
负责人:Marc Kevin Jenkins
-
依托单位:
Modular Subunit Vaccine for Salmonella
-
批准号:7111197
-
项目类别:
-
资助金额:$29.9万
-
财政年份:2005
-
负责人:Marc Kevin Jenkins
-
依托单位:
Modular Subunit Vaccine for Salmonella
-
批准号:7234300
-
项目类别:
-
资助金额:$32.66万
-
财政年份:2005
-
负责人:Marc Kevin Jenkins
-
依托单位:
Modular Subunit Vaccine for Salmonella
-
批准号:7092457
-
项目类别:
-
资助金额:$23.67万
-
财政年份:2005
-
负责人:Marc Kevin Jenkins
-
依托单位:
Modular Subunit Vaccine for Salmonella
-
批准号:7618271
-
项目类别:
-
资助金额:$32.04万
-
财政年份:2005
-
负责人:Marc Kevin Jenkins
-
依托单位:
Modular Subunit Vaccine for Salmonella
-
批准号:7808016
-
项目类别:
-
资助金额:$31.72万
-
财政年份:2005
-
负责人:Marc Kevin Jenkins
-
依托单位:
海外基金